How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 11 Jul | 18 Jul | 25 Jul | 24 Aug | 28 Aug | 04 Sep | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 76.2 | 75.0 | 75.0 | 73.5 | 73.5 | 73.5 | -2.7 |
| Healthcare | 19.9 | 22.0 | 22.0 | 22.4 | 22.4 | 22.4 | +2.5 |
| Unclassified | · | · | · | 0.9 | 0.9 | 0.9 | 0.0 |
| Chemicals | 0.6 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | +0.1 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| TORNTPHARM | Pharma | 9.94% | 7 | 8 | 5 | 4 | 1 | — | +7.0% |
| SUNPHARMA | Pharma | 9.75% | 7 | 8 | 7 | 8 | 5 | — | +1.5% |
| APOLLOHOSP | Healthcare | 7.08% | 9 | 5 | 5 | 2 | 2 | — | +0.4% |
| CIPLA | Pharma | 4.56% | 4 | 3 | 6 | 4 | 7 | — | -3.9% |
| AUROPHARMA | Pharma | 4.29% | 8 | 3 | 10 | 6 | 7 | — | +9.9% |
| AJANTPHARM | Pharma | 4.17% | 8 | 10 | 1 | 3 | 3 | — | +13.9% |
| SAILIFE | Healthcare | 3.89% | 9 | 10 | 5 | 9 | 1 | Leader | +27.8% |
| MANKIND | Pharma | 3.58% | 4 | 8 | 9 | 3 | 5 | — | -6.1% |
| LUPIN | Pharma | 3.51% | 3 | 10 | 10 | 7 | 9 | — | -11.1% |
| ABBOTINDIA | Pharma | 3.35% | 3 | 9 | — | 6 | 8 | — | -3.8% |
| EMCURE | Pharma | 3.24% | 10 | 10 | 9 | 10 | 4 | Leader | +7.6% |
| FORTIS | Healthcare | 2.98% | 4 | 8 | 5 | 5 | 6 | — | -12.4% |
| IPCALAB | Pharma | 2.47% | 9 | 5 | 1 | 3 | 4 | — | +14.3% |
| GLAND | Pharma | 2.34% | 10 | 7 | 5 | 4 | 4 | Leader | +27.9% |
| SHILPAMED | Pharma | 2.32% | 8 | 9 | 6 | 1 | 1 | — | +72.0% |
| CORONA | Pharma | 2.29% | 5 | 9 | 7 | 2 | 1 | — | +14.6% |
| PGHL | Pharma | 2.16% | 4 | 4 | 1 | 8 | 5 | — | -13.0% |
| LALPATHLAB | Healthcare | 2.12% | 7 | 8 | 7 | 5 | 3 | — | +18.6% |
| JLHL | Healthcare | 2.03% | 1 | 9 | 4 | 2 | 10 | — | -83.0% |
| DIVISLAB | Pharma | 1.95% | 9 | 8 | 1 | 4 | 1 | — | +38.4% |
| THYROCARE | Pharma | 1.91% | 7 | 10 | 8 | 9 | 2 | — | +1.4% |
| ALKEM | Pharma | 1.88% | 3 | 8 | 7 | 6 | 8 | — | -6.6% |
| METROPOLIS | Pharma | 1.59% | 8 | 9 | 6 | 7 | 1 | — | +4.7% |
| PFIZER | Healthcare | 1.26% | 5 | 7 | 1 | 8 | 7 | — | -2.9% |
| BIOCON | Pharma | 1.26% | 4 | 1 | 10 | 2 | 7 | — | -8.8% |
| PPLPHARMA | Pharma | 1.16% | 10 | 1 | 5 | 9 | 5 | Leader | +28.4% |
| ANTHEM | Pharma | 1.07% | 10 | 10 | 6 | 3 | 1 | Leader | +16.3% |
| DRREDDY | Pharma | 1.06% | 2 | 2 | 6 | 10 | 9 | — | -14.7% |
| VIJAYA | Pharma | 0.98% | 7 | 10 | 5 | 4 | 1 | — | +10.1% |
| MEDIASSIST | Healthcare | 0.87% | 4 | 7 | 9 | 8 | 7 | — | -8.2% |
| GLAXO | Healthcare | 0.80% | 8 | 7 | 2 | 8 | 4 | — | +31.0% |
| VINATIORGA | Chemicals | 0.78% | 1 | 9 | 1 | 7 | 7 | — | -3.6% |
| MAXHEALTH | Healthcare | 0.72% | 1 | 9 | 6 | 5 | 6 | — | -6.0% |
| SYNGENE | Healthcare | 0.68% | 1 | 2 | 6 | 7 | 7 | — | -17.8% |
| JUBLPHARMA | Pharma | 0.55% | 3 | 1 | 3 | 3 | 7 | — | -5.2% |
Performance · 5.0y
Over the last 5.0 years ₹100 in the fund grew to ₹185 (+85%), vs ₹156 for Nifty 500 (+56%) and ₹137 for Nifty 50 (+37%). Its relative-strength line ended at 135 vs Nifty 50 and 118 vs Nifty 500 — above 100, sustained outperformance.